Development of the forebrain involves the migration of GABAergic interneurons over long distances from ventral into dorsal regions. Although defects in interneuron migration are implicated in neuropsychiatric diseases such as Epilepsy, Autism, and Schizophrenia, model systems to study this process in humans are currently lacking. Here, we describe a method for analyzing human interneuron migration using 3D organoid culture. By fusing cerebral organoids specified toward dorsal and ventral forebrain, we generate a continuous dorsal--ventral axis. Using fluorescent reporters, we demonstrate robust directional GABAergic interneuron migration from ventral into dorsal forebrain. We describe 
Introduction
The cerebral cortex contains two main populations of neurons, excitatory glutamatergic pyramidal neurons, and inhibitory γ--Aminobutyric acid (GABA) producing interneurons 1 .
Excitatory cortical neurons are predominantly generated by dorsal forebrain progenitors, while inhibitory GABAergic cortical interneurons are generated by ventral forebrain progenitors 2 . To integrate into cortical circuits, interneurons perform a long--distance migration from their ventral origin into their target dorsal cortical regions 3 . This long--range tangential migration is controlled by many signaling pathways 4, 5 , and studies using animal models indicate that mutations in some neurological disease--associated genes can disrupt interneuron migration 6, 7 . However, the relationship between patient--specific mutations and human brain development remains enigmatic without suitable experimental human model systems.
Three--dimensional (3D) organoid culture technology allows the development of complex, organ--like tissues reminiscent of in vivo development 8 . Importantly, cerebral organoids recapitulate many aspects of embryonic cortical development including the generation of diverse cell types corresponding to different brain regional identities 9 . For instance, cerebral organoids can produce dorsal and ventral forebrain progenitors that generate excitatory neurons and inhibitory interneurons, respectively 9 . Moreover, cerebral organoids can be generated from human patient--derived induced pluripotent stem cells (hiPSCs), and used for functional genomic studies of neurological disorders such as microcephaly 9 and Autism 10 . Therefore, cerebral organoids represent an exemplary experimental system to study the role of neurological disease--associated genes in brain development. In the current study, we focused on expanding the cerebral organoid model system by enhancing the phenotypic analyses to include neuronal migration. We developed an organoid co--culture "fusion" paradigm to successfully combine independently patterned organoids into a single tissue. Using this approach, we recreated the dorsal--ventral forebrain axis, and by labeling one organoid with a fluorescent reporter, we observed robust migration of cells between fused organoids. The molecular taxonomy and migratory dynamics of these cells resembles that of cortical interneurons. Therefore, we developed an organoid fusion assay that allows analysis of human cortical interneuron migration. This technology enhances the repertoire of phenotypic assays available for cerebral organoids, and in turn the complexity of phenotypes that can be used to study the developmental cell biology of human neurological diseases.
Results

Drug--patterning of cerebral organoids enhances the production of ventral forebrain identity.
The cerebral organoid method 9 is capable of producing many different brain regions, including dorsal and ventral forebrain. As it relies on intrinsic patterning, however, the production of some regions is variable and infrequent, especially more ventral (NKX2--1+)
interneuron progenitor regions (Renner at al, EMBO J, in press). To increase the consistency and yield of ventral--forebrain interneuron progenitor regions, we modified the organoid protocol 9, 11 to include a ventral drug--treatment ( Figure 1A ). Based on previous 2D--neuronal differentiation 12 --14 protocols, we utilized a combination of WNT--inhibition and enhanced SHH signaling to promote a rostro--ventral forebrain identity. qPCR analysis of the ventral organoids revealed a significant increase in expression of the forebrain marker FOXG1 15, 16 ( Figure 1B ,C). The dorsal forebrain marker TBR1 17 became undetectable, while the ventral forebrain marker DLX2 18--20 was dramatically increased in ventral organoids compared to control organoids ( Figure 1B ,C). To further confirm the successful ventralization of cerebral organoid tissue, we examined the expression of specific markers of ventral forebrain ganglionic eminence (GE) subregions that produce interneurons of different subtypes 3,21--23 .
GSX2 is expressed in the dorsal--lateral GE (LGE) and caudal GE (CGE), NKX2--1 is expressed in the ventral--medial GE (MGE), while LHX6 is expressed in a subregion of the MGE producing more ventral--derived MGE (vMGE) interneurons 3, 20, 21, 24, 25 ( Figure 1B ). GSX2 was expressed in control organoids, but further increased in ventral organoids ( Figure 1C ). Expression of NKX2--1 and LHX6 was undetectable in control organoids, but largely increased in ventral organoids ( Figure 1C ). Finally, immunostaining confirmed the qPCR results indicating widespread expression of FOXG1 in control and ventral organoids, but only ventral organoids expressed the ventral forebrain marker NKX2--1 ( Figure 1D ). Intriguingly, control organoids widely expressed dorsal forebrain markers for both progenitors (PAX6) 26 and early born neurons (TBR1) 17 ( Figure 1E ). In contrast, ventral organoids contained only small regions of PAX6 + or TBR1 + tissue ( Figure 1E ). Therefore, these results confirm the successful production of ventral cerebral organoids at the expense of dorsal tissue upon ventral drug--treatment.
Fused cerebral organoids recapitulate a continuous dorsal--ventral forebrain axis and long--distance cell migration.
To recreate the complete dorsal--ventral identity axis in a single tissue, we developed an organoid co--culture method, which we termed organoid "fusion". Control organoids produced mostly dorsal forebrain tissue ( Figure 1C ,E). However, inhibition of SHH activity with the smoothened receptor inhibitor cyclopamine A (CycA) can enhance dorsal forebrain identity in 2D neuronal differentiation from hPSCs 27 . Therefore, to support dorsal identity, organoids were treated with CycA during the neural induction step of the cerebral organoid protocol ( Figure 2A ). In this approach, embryoid bodies (EBs) are individually patterned into either dorsal (CycA) or ventral (IWP2+SAG) forebrain organoids (Figure 2A ,B). After patterning treatments, a ventral and a dorsal EB are embedded together within a single Matrigel droplet (Figure 2A ), and over time the organoids grow together and become fused ( Figure 2B ). Immunostaining of fused ventral::dorsal organoids revealed the production of a continuous tissue where one side was highly positive for the ventral marker NKX2--1, while the opposite side was positive for the dorsal marker TBR1 ( Figure 2C ). Therefore, the organoid fusion method allows dorsal and ventral forebrain regions to be juxtaposed in an arrangement similar to that occurring during brain development. To test whether cells could migrate between the fused organoids we used cell lines containing a ubiquitous GFP reporter to create ventral/GFP + ::dorsal organoid fusions.
Immunofluorescent analysis showed many GFP + cells from the ventral organoid within the GFP --dorsal organoid ( Figure 2D ). Migrating cells were observed in small numbers around day 30 ( Figure 2D ,E). Their density drastically increased from day 30 to 46, but we did not observe a significant increase from day 46 to 80 ( Figure 2E ). Since the organoids increase in size with age, the absolute numbers of migrated cells must increase over time to maintain a similar density. Moreover, the cells appeared more dispersed throughout the dorsal regions in 80 day old organoids ( Figure 2D ). Therefore, based on these results, we focused our future analysis on organoids older than 60 days old.
Mixing the tissue components of cerebral organoid fusions indicates directed ventral--to--dorsal cortical cell migration.
During in vivo brain development, GABAergic interneurons originate in ventral forebrain progenitor regions before they migrate to their dorsal forebrain target 4, 5 . To test whether this directionality is recapitulated in fused organoids, we varied the identities of Figure   3C ). These data confirm our initial observation of directionally biased migration from ventral into dorsal organoid tissue, and strongly suggests that the migration between fused organoids resembles interneuron migration. Finally, this experiment shows that ventral::dorsal fused organoids produce the most robust migration between organoids.
GABAergic interneurons migrate between fused cerebral organoids.
Since our previous experiments suggested that the migration in ventral::dorsal organoid fusions resembles interneuron migration, we first tested whether the migrating cells were GABAergic by examining whether the migrating GFP + cells expressed GAD1, one of the key enzymes for the synthesis of GABA 28 . Immunostaining revealed that the GFP + cells that had migrated into the target organoid broadly expressed GAD1 ( Figure 4A --C). Strikingly, when visualizing the entire organoid, GAD1 was expressed in a similar pattern as the GFP + migrating cells ( Figure 4A ). Additionally, the expression of GAD1 appeared stronger in regions near the edge of the organoid ( Figure 4B) 31 . We observed that the GFP + cells expressed DCX ( Figure   4E ), confirming their neuronal identity, and a subset also expressed NeuN ( Figure 4E Figure 4E ), and appear to be predominantly GABAergic interneurons ( Figure 4A ,B), we next tested which interneuron subtypes are produced. Interneurons are particularly heterogeneous and multiple molecular markers can be used to identify various subtypes 32, 33 that are generated by distinct progenitor subpopulations within the ventral forebrain 3,20--23,34 . In humans, the majority of interneurons are generated from NKX2--1 + regions of the MGE 35, 36 . Therefore, we tested whether the migrating GFP + cells produce MGE--derived interneuron subtypes. In humans, SOX6 is expressed in the MGE and in immature and mature interneurons emerging from this region 35 . In organoid fusions, we observed multiple SOX6 + MGE interneurons among the GFP + migrating cells GFP + cells that were also GAD1 + ( Figure 5A ). Therefore, MGE--derived interneurons can be generated within cerebral organoid fusions. To confirm this finding, we also examined the expression of markers for MGE--derived interneurons 3, 33, 34 . We observed expression of somatostatin (SOM) ( Figure 5B ), neuropeptide Y (NPY) ( Figure 5C ) calbindin D--28k (CB) ( Figure 5D ), and parvalbumin (PV) ( Figure 5E ) by GFP+ migrated interneurons (GAD1+ or VGAT+). Therefore, in organoid fusions, multiple MGE--derived interneuron subtypes can be generated. The remaining interneurons in the human brain arise from the LGE/CGE 3, 33, 34 . Similar to SOX6 for MGE, the transcription factors COUP--TFII/NR2F2 and SP8 can be used as
LGE/CGE fate--mapping markers for cortical interneurons 35 . Both SP8 ( Figure 5F ) and COUP--TFII ( Figure 5G ) were expressed by GFP + migrating interneurons (GAD1 + ) in organoid fusions.
As confirmation of this result, we also analyzed the expression of markers for LGE/CGE-- The chemoattractant SDF--1 (CXCL12) and its receptor CXCR4 regulate the tangential migration of interneurons 44 . To test if the migration we observed in cerebral organoid fusions is CXCR4--dependent, we created long--term slice cultures of organoid fusions that we treated with the CXCR4 antagonist, AMD3100. Compared to untreated control slices prepared from the same organoid fusion, the density of migrating GFP + cells into GFP --dorsal regions was significantly reduced upon AMD3100 treatment. Therefore, the cell migration in cerebral organoid fusions depends on CXCR4 activity. Combined with our previous data, this result confirms that the cell migration observed in cerebral organoid is consistent with that of tangentially migrating interneurons.
Discussion
In this study, we developed a cell migration assay using fused cerebral organoids.
The concept of fusing organoids is based on classical co--culture experiments. However, our method represents an adaptation and extension of this technique to study human neuronal cell migration with the experimental control allowed by in vitro 3D cell culture. Ventral--dorsal organoid fusions exhibit robust long--distance cell migration resembling that of ventral forebrain--derived cortical inhibitory interneurons. This is based on multiple pieces of data. First, we observed substantially more migration from ventral into dorsal forebrain regions in cerebral organoid fusions. Second, the migrating cells within organoid fusions express GABAergic markers (GAD1/VGAT). Third, the migrated GFP + cells can produce a variety of interneuron subtypes. In addition, the lack of RELN expression by migrating GFP + cells supports a ventral forebrain--derived interneuron identity. Fourth, the migration dynamics of the GFP + cells in fused organoids resembles the characteristic migratory behavior exhibited by interneurons migrating tangentially within the cortex. Finally, the cell migration in organoid fusions was inhibited by CXCR4 inhibition as observed for tangentially migrating interneurons in developing mouse cortex. Therefore, we have recapitulated the migration of human cortical interneurons from ventral in dorsal forebrain regions.
Moreover, the observance that these cells exhibit both immature and mature neuronal markers indicates their ability to undergo maturation once arriving in their dorsal cortical forebrain target regions. This represents the exciting opportunity to recreate a developing human cortical circuit containing an enhanced repertoire of cellular diversity than was possible to achieve within the previous singular organoid method.
An exciting future application of this technique will be to study human developmental biology and its relationship to neurological diseases. With this in mind while characterizing this assay, we present different experimental paradigms, each of which can be used to investigate various aspects and scientific questions related to neuronal cell migration. For instance, the labeling of the cells within one of the fused organoids with a fluorescent reporter allows the visualization of long--distance neuronal migration. This can even be continuously monitored over time through whole--mount imaging of intact organoid fusions.
In addition, the identity of the cells can be easily examined using immunostaining for identification of neuronal subtypes. This is useful because many psychiatric diseases, such as Schizophrenia, are thought to involve selective deficits in specific interneuron subpopulations 45 .
A second type of analysis is dissecting the role of specific molecules on neuronal migration to determine if they are acting in a cell--autonomous or cell non--autonomous manner. For instance, using our organoid mixing paradigm, organoids from either the origin of migration or the target can be genetically manipulated independently by deriving the origin and target organoids from distinct cell lines containing either mutant or wild--type alleles of a gene of interest. This is a powerful genetic tool routinely used in genetic model organisms, but can now also be utilized in 3D cultures of developing human brain tissue.
We also present an organoid fusion slice culture paradigm in which confocal time--lapse
imaging can be used to analyze the short--term dynamics of neuronal cell migration. This is an important tool because some molecules such as GABA are known to affect the motility of migrating interneurons 4 , which may produce a subtle phenotype in a long--term migration assay, and therefore instead require a higher time--resolution analysis of the dynamics of migrating cells. In addition, long--term slice cultures can be used to test how different drug--treatments can affect cell migration. This presents the opportunity to perform drug--screens to determine the effect of many different molecules on interneuron migration.
Finally, the organoid fusion method also presents unique applications beyond cell migration, which can be developed further in the future. As one example, we observed substantial neurite dynamics with the appearance of axon projections. In addition, although we specifically focused on ventral--dorsal forebrain fusions, the organoid fusion paradigm allows flexibility in the brain regional identities that can be grown together. Combined with the additional brain--region specific organoid protocols 46--49 , the possible brain circuits that could be modeled using organoid fusions is vast. Therefore, organoid fusion technology greatly enhances the phenotypic analyses possible in cerebral organoids, and the flexibility of the method immensely expands the future development of in vitro models of human neurological diseases.
Methods
Cell culture
Feeder Standard procedures were used for culturing and splitting hPSCs as explained previously 11 .
All cell lines were routinely tested for contamination and confirmed mycoplasma--negative. 
Cloning/Molecular biology/Generating hPSC lines
Cerebral organoid generation and fusion
Cerebral organoids were generated following the previous protocol developed in our was removed by washing 10 minutes in PBS using a slide rack (Sigma, Wash--N--Dry). The sections were post--fixed directly on the slides using 4% PFA for 10 minutes at RT followed by washing 3x10 minutes in PBS. The tissue area was outlined using a hydrophobic PAP pen.
Permeabilization/blocking was performed using 5% BSA/0.3% TX100 in PBS with 0.05% sodium azide and incubated 30 minutes at room temperature (RT) within a dark humidified slide box. Primary antibodies (a table of used primary and secondary antibodies can be found at the end of the method section) were added at the desired dilutions in antibody solution (5% BSA, 0.1% TX100 in PBS with 0.05% sodium azide) and incubated overnight at 
Imaging/Microscopy
Fluorescent cell culture imaging was performed using a Zeiss Axio Vert.A1 widefield microscope and an Axiocam ERc 5s camera (Zeiss, Zeiss GmbH) using Zeiss Plan--Neofluar format using Handbrake software to generate the supplemental movies.
For generation of figures and presenting images, the "crop" function, and changing the max/min levels using the "Brightness/Contrast" function of Fiji were used.
Cell density quantification
The number of GFP + cells migrating into GFP --target regions of cerebral organoid fusions was counted manually using the "Cell Counter" plugin of Fiji. The GFP --area in organoid fusions was outlined with the ROI tool and the area calculated using the "measure" function. The cell counts were divided by the area to determine the density of image containing the GFP --region was used for counting.
Statistics
All graphs and statistical analyses were generated using Prism 7 (GraphPad). When comparing only two groups ( Figure 1C, 6E ) an unpaired two--tailed Student's t--test was performed, for the remaining data comparing multiple groups a one--way ANOVA with posthoc Tukey's test was used ( Figure 2F, 3C ). Samples were tested for normality prior to testing statistical significance. No statistical methods were used to predetermine the sample size. Sample sizes for experiments were estimated based on previous experience with a similar setup that showed significance. Experiments were not randomized and investigator was not blinded. DLX2  ACGTCCCTTACTCCGCCAAG  AGTAGATGGTGCGGGGTTTCC  FOXG1  TGGCCCATGTCGCCCTTCCT  GCCGACGTGGTGCCGTTGTA  GSX2  CACCGCCACCACCTACAAC  CAGGAGTTGCGTGCTAGTGA  LHX6  CCGTCTGCAGGCAAGAACAT GACACACGGAGCACTCGAG  NKX2--1  GCCGTACCAGGACACCATG  ATGTTCTTGCTCACGTCCCC  TBP  GGGCACCACTCCACTGTATC  CGAAGTGCAATGGTCTTTAGG  TBR1 CTCAGTTCATCGCCGTCACC AGCCGGTGTAGATCGTGTCATA GFP  PV  GAD1   GFP  SOM  GAD1  GFP  SOM  GAD1   GFP  CB  GAD1  GFP  CB  GAD1   GFP  CR  VGAT  GFP  CR  VGAT   GFP  SOX6 GAD1  GFP  SOX6  GAD1   GFP  SP8  GAD1  GFP  SP8  GAD1   GFP COUP-TFII VGAT  GFP  COUP-TFII  VGAT   20 
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